MedPath

SHINSHU UNIVERSITY

SHINSHU UNIVERSITY logo
🇯🇵Japan
Ownership
Private
Established
1949-05-01
Employees
501
Market Cap
-
Website
http://www.shinshu-u.ac.jp

Clinical Trials

167

Active:0
Completed:77

Trial Phases

4 Phases

Phase 1:6
Phase 2:10
Phase 4:5
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (165 trials with phase data)• Click on a phase to view related trials

Not Applicable
144 (87.3%)
Phase 2
10 (6.1%)
Phase 1
6 (3.6%)
Phase 4
5 (3.0%)

Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)

Phase 2
Recruiting
Conditions
T2DM (Type 2 Diabetes Mellitus)
SGLT2-Inhibitors
Metformin
Interventions
First Posted Date
2022-07-22
Last Posted Date
2022-07-22
Lead Sponsor
Shinshu University
Target Recruit Count
120
Registration Number
NCT05469659
Locations
🇯🇵

Shinshu University, Matsumoto, Nagano, Japan

Usefulness of Non TNF Usage in RA Patients

Phase 2
Recruiting
Conditions
Rheumatoid Arthritis
First Posted Date
2018-12-21
Last Posted Date
2021-09-21
Lead Sponsor
Shinshu University
Target Recruit Count
90
Registration Number
NCT03784261
Locations
🇯🇵

Yukio Nakamura, Matsumoto, Nagano, Japan

Examination of Efficacy and Safety of Baricitinib in RA Patients

Phase 2
Recruiting
Conditions
Rheumatoid Arthritis
Interventions
Drug: "Biologics"
Drug: "Baricitinib", "olumiant®"
First Posted Date
2018-11-28
Last Posted Date
2021-09-21
Lead Sponsor
Shinshu University
Target Recruit Count
90
Registration Number
NCT03755466
Locations
🇯🇵

Yukio Nakamura, Matsumoto, Nagano, Japan

Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

Phase 2
Recruiting
Conditions
Osteoporosis
Interventions
Drug: SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"
Drug: Bisphosphonates and ELD "Edirol®Tablet 0.75ug"
Drug: ELD "Edirol®Tablet 0.75ug"
First Posted Date
2018-11-27
Last Posted Date
2021-09-21
Lead Sponsor
Shinshu University
Target Recruit Count
90
Registration Number
NCT03755193
Locations
🇯🇵

Yukio Nakamura, Matsumoto, Nagano, Japan

Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy

Phase 2
Recruiting
Conditions
Osteoporosis
Interventions
Drug: "Teriparatide", "Forteo® or Teribon"
First Posted Date
2018-10-10
Last Posted Date
2021-09-21
Lead Sponsor
Shinshu University
Target Recruit Count
90
Registration Number
NCT03702140
Locations
🇯🇵

Yukio Nakamura, Matsumoto, Nagano, Japan

  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.